63324 Efficacy of zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, evaluated by Physician's Global Assessment×Body surface area (PGA×BSA), in a randomized phase 2b trial in moderate-to-severe plaque psoriasis
Recommended Citation
Stein Gold LF, Green L, Blau J, Zhang W, Uy J, Winkelman W, Kircik L. 63324 Efficacy of zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, evaluated by Physician's Global Assessment×Body surface area (PGA×BSA), in a randomized phase 2b trial in moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2025; 93:AB192.
Document Type
Conference Proceeding
Publication Date
9-1-2025
Publication Title
J Am Acad Dermatol
Abstract
Background: Zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, achieved its primary endpoint (PASI-75) with doses of ≥5mg in a phase 2b trial of patients with moderate-to-severe plaque psoriasis (NCT04999839); 33% of patients receiving zasocitinib 30mg achieved PASI-100 at week 12. PGAxBSA, a more efficient and simpler tool than PASI for assessing psoriasis severity and extent, strongly correlates with PASI and is more sensitive to BSA changes. Methods: In this randomized, multicenter, double-blind, placebo-controlled trial, patients received oral zasocitinib (2mg, 5mg, 15mg or 30mg) or placebo (1:1:1:1:1) once daily for 12 weeks. This post-hoc analysis assessed least-squares mean (LSM) percentage change from baseline in PGA×BSA, relationship between PGA×BSA and PASI or DLQI using Spearman’s correlation coefficients (ρ) and proportion of patients achieving 75% improvement in PGA×BSA at week 12. Results: Patients receiving zasocitinib achieved significantly greater percentage reductions in PGA×BSA at week 12 than placebo when measured via LSM (placebo [n=52]: −22.9%; 2mg [n=50]: −43.3%, p=0.005; 5mg [n=52]: −62.1%, p<0.001; 15mg [n=53]: −82.7%, p<0.001; 30mg [n=52]: −78.4%, p<0.001). Strong correlations between PGA×BSA and PASI (observed and percentage change from baseline scores) were observed at week 12 for all zasocitinib groups and placebo (ρ=0.95). Correlations between PGA×BSA and DLQI scores were moderate (ρ=0.53–0.55). Equivalent proportions of zasocitinib-treated patients achieved 75% reduction in PGA×BSA and PASI at week 12 (2mg: 18.0%; 5mg: 44.2%; 15mg: 67.9%; 30mg: 67.3%). Conclusions: Zasocitinib improved PGA×BSA versus placebo. Strong correlations between PGA×BSA and PASI were observed, validating use of PGA×BSA in routine clinical practice.
Volume
93
First Page
AB192
